复星医药(02196)子公司就丁二酸复瑞替尼胶囊再次递交的药品注册申请获国家药监局受理

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanbang, has submitted a drug registration application for SAF-189, a new drug aimed at treating ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) [1] Group 1 - The drug registration application has been accepted by the National Medical Products Administration [1] - SAF-189 is classified as a Class 1 chemical drug [1] - The indication for this new drug is specifically for patients with ALK-positive NSCLC [1]